产品
编 号：F155575
分子式：C28H22Cl3N3O5
分子量：586.85
分子式：C28H22Cl3N3O5
分子量：586.85
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1418274-28-8
产品详情
生物活性：
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.
体内研究：
在非酒精性脂肪性肝炎 (NASH) 大鼠中，Cilofexor (GS-9674；30 mg/kg；口服强饲法；每天一次；持续 10 周；雄性 Wistar 大鼠) 处理显著增加回肠中的 Fgf15 表达并降低肝脏中的 Cyp7a1。肝纤维化和肝胶原表达明显减少。Cilofexor 还可以显著降低肝星状细胞 (HSC) 的活化并显著降低门静脉压力，而不影响全身血流动力学。Animal Model:Male Wistar rats received a choline-deficient high fat diet (CDHFD)
Dosage:30 mg/kg
Administration:Oral gavage; once daily; for 10 weeks
Result:Significantly increased Fgf15 expression in the ileum and decreased Cyp7a1 in the liver. Liver fibrosis and hepatic collagen expression were significantly reduced.
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.
体内研究：
在非酒精性脂肪性肝炎 (NASH) 大鼠中，Cilofexor (GS-9674；30 mg/kg；口服强饲法；每天一次；持续 10 周；雄性 Wistar 大鼠) 处理显著增加回肠中的 Fgf15 表达并降低肝脏中的 Cyp7a1。肝纤维化和肝胶原表达明显减少。Cilofexor 还可以显著降低肝星状细胞 (HSC) 的活化并显著降低门静脉压力，而不影响全身血流动力学。Animal Model:Male Wistar rats received a choline-deficient high fat diet (CDHFD)
Dosage:30 mg/kg
Administration:Oral gavage; once daily; for 10 weeks
Result:Significantly increased Fgf15 expression in the ileum and decreased Cyp7a1 in the liver. Liver fibrosis and hepatic collagen expression were significantly reduced.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备